-+ 0.00%
-+ 0.00%
-+ 0.00%
vTv Therapeutics says FDA grants orphan drug designation to HPPD in sickle cell disease
Share
Listen to the news
vTv Therapeutics says FDA grants orphan drug designation to HPPD in sickle cell disease
  • FDA granted Orphan Drug Designation to vTv Therapeutics’ HPPD for sickle cell disease.
  • HPPD is an oral Nrf2/Bach1 modulator in preclinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610071601PRIMZONEFULLFEED9841475) on October 07, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending